DECOY THERAPEUTICS INC (DCOY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.69-6.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DCOY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -44.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
DCOY — private placement
Dated 2026-06-29
Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 26, 2026, Decoy Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an institutional and accredited investor (the “Purchaser”) for a private placement of the Company’s securities (the “Private Placement”). The closing of the Private Placement is expected to occur on or about June 29, 2026 (the “Closing” and such date,…
Why it matters: Decoy is back in compliance. It is under a one-year watch. If it fails again, it may get delisted.
Worry ifThere were no compliance issues in the one-year monitoring period.
Less concerning ifNasdaq sent a notice. It was about not following the rules during the monitoring period.
Why it matters: Advancing the lead asset into clinical trials is key for Decoy's future. Delays could harm prospects.
Supportive ifThey announced the start of clinical trials for the main asset.
Worry ifNo updates on clinical trials or further delays in the timeline.
Why it matters: Fixing the Nasdaq listing issue is important. It helps keep the company's stock listed.
Worry ifThe company shares good news about meeting the minimum bid price rule.
Less concerning ifThe company fails to meet the minimum bid price rule again, risking delisting.
Why it matters: Decoy regained Nasdaq compliance but is under a one-year monitoring period. This is crucial for its listing.
Worry ifNasdaq sent a notice. It says Decoy meets the minimum bid price rule.
Less concerning ifNasdaq sent a letter about delisting. This is due to not meeting the minimum bid price rule.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$389 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $1,096 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,207 loss on $10,000 · 82.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If Decoy Therapeutics fails to meet the $1.00 bid price, it risks delisting. This could hurt investor confidence and stock value.
Worry ifThe closing bid price remains below $1.00 for 30 consecutive business days.
Less concerning ifThe closing bid price rises above $1.00 for 30 consecutive business days.
Why it matters: Progress on clinical trials is essential for Decoy's growth. It impacts investor confidence and funding.
Supportive ifDecoy filed a Clinical Trial Application. This is to start a Phase 1 trial.
Worry ifThere are delays or problems with filing the Clinical Trial Application for the main asset.